Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Device labeling symbols on EU-marketed devices need to be accompanied by explanation, exec advises.

This article was originally published in The Gray Sheet

Executive Summary

DEVICE LABELING SYMBOLS ON EU-MARKETED DEVICES need to be accompanied by explanatory text, Howard Dobbs, director of international regulatory affairs for Smith & Nephew North America, advised attendees at a June 4 session of the Medical Design and Manufacturing East conference in New York City. Dobbs said that symbols must be explained because the European Commission has not yet harmonized a European Standard for symbols. The issue is particularly problematic in light of the June 14, 1998 implementation date for the EU's Medical Devices Directive (MDD). Compliance with the directive has been optional since January 1995 ("The Gray Sheet" July 17, 1995, p. 20).

You may also be interested in...

Dr Reddy's Strengthens Russian OTC Portfolio Through Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.

Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

Sanofi's Dupixent Cleared For Children With Atopic Dermatitis In EU

The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts